KM 819

Drug Profile

KM 819

Alternative Names: KM-819; KR-33493

Latest Information Update: 24 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chungnam National University; Korea Research Institute of Chemical Technology
  • Developer Chungnam National University; Kainos Medicines; Korea Research Institute of Chemical Technology
  • Class Antiparkinsonians
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Parkinson's disease (In volunteers) in South Korea (PO) (NCT03022799)
  • 13 Apr 2016 Preclinical trials in Parkinson's disease in South Korea (PO) before April 2016
  • 13 Apr 2016 Korea FDA approves IND application for initiation of a phase I trial of KR 33493 in Parkinson's disease (Kainos Medicine pipeline, April 2016) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top